FDA Chases Another Synthetic Stimulant Off Supplement Ingredient Menu
This article was originally published in The Tan Sheet
Executive Summary
CFSAN tells 14 firms the stimulant DMBA – identified by names including 1,3-dimethylbutylamine, 2-amino-4-methylpentane, AMP citrate and 4-methyl-2-pentanamine – has “no history of use or other evidence of safety … when used as a dietary ingredient.”
You may also be interested in...
Kirkman Acquires Rose, IQ Recalls Picamilon Supplement: Health And Wellness Industry News Roundup
Recalls reported by FDA for health and wellness products.
Hi-Tech Lawsuit Calls FDA DMAA Enforcement “Bullying Tactics”
Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.